Abdominal Aortic Aneurysm Treatment Market By Treatment Type (Standard Endovascular Aneurysm Repair, Complex Endovascular Aneurysm Repair/Fenestrated & Branched EVAR, Open Surgical Repair); By Product Type (Aortic Stent Grafts, Fenestrated & Branched Stent Grafts, Catheters & Guidewires, Balloons & Closure Devices, Surgical Vascular Grafts, Endoleak Embolization & Revision Devices); By Procedure Type (Elective Intact AAA Repair, Ruptured/Urgent AAA Repair, Post-EVAR Revision & Secondary Intervention, Surveillance & Diagnostic Follow-Up); By End User (Hospitals & Specialized Vascular Centers, Outpatient Vascular Clinics, Diagnostic Imaging & Surveillance Centers, Emergency & Trauma-Enabled Vascular Units); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Abdominal Aortic Aneurysm Treatment Market: EVAR Expansion, Complex Repair, and Surveillance Economics Reshape Aortic Care

The Global Abdominal Aortic Aneurysm Treatment Market was valued at USD 2.65 billion in 2025 and is projected to reach USD 3.94 billion by 2032, growing at a CAGR of 5.81%, according to Strategic Market Research.

 

Abdominal aortic aneurysm treatment requires a broad care approach. Key options include endovascular repair, open surgery, vascular grafts, diagnostic imaging and post-repair surveillance. Patients are usually monitored until the aneurysm becomes symptomatic, grows rapidly or reaches the threshold for repair.

 

An estimated 35.12 million people aged 30–79 were living with abdominal aortic aneurysm in 2019, representing a global prevalence of 0.92%. Prevalence was 1.46% in men and 0.39% in women. The Western Pacific recorded the highest regional prevalence at 1.31%, compared with 0.33% in Africa. Smoking, older age, hypertension, cardiovascular disease, obesity and family history remain major risk factors.

 

Aortic aneurysms caused an estimated 153,927 deaths globally in 2021, up 74.2% from 1990, although the age-standardized death rate declined to 1.86 per 100,000. Ruptured AAA carries an overall mortality rate of approximately 65% to 90%, making early detection and elective repair central to reducing deaths.

 

In the United States, about 200,000 people are diagnosed with AAA each year and approximately 10,000 die following rupture. Repair is generally considered when aneurysm size, growth rate, symptoms and patient risk indicate a meaningful likelihood of rupture.

 

India also represents an emerging treatment need. Earlier estimates suggested that approximately 0.6 million people were affected, although consistent national mortality and screening data remain limited.

 

Repair Eligibility Narrows the Treatable Population

Abdominal aortic aneurysms are generally considered for repair when they reach approximately 5.0–5.5 cm, cause symptoms, or expand quickly. Smaller aneurysms usually remain under ultrasound or CT surveillance because no approved medicine can shrink the aneurysm or remove the risk of future rupture.

Treatment decisions also depend on sex, anatomy, operative fitness, growth rate, life expectancy, and the balance between rupture risk and procedural complications. These criteria separate the patient population into initial detection, recurring surveillance, elective repair, urgent repair, and post-procedure management. Each stage generates different demand for imaging, implants, hospital resources, and specialist care.

 

EVAR Has Become the Main Treatment Pathway

Endovascular aneurysm repair places a stent graft inside the aorta through catheter-based access, usually through the femoral arteries. Open repair replaces the weakened section of the aorta with a surgically implanted synthetic graft. EVAR generally involves less invasive access and a shorter recovery, while open surgery remains necessary for patients with unsuitable anatomy, infected aneurysms, connective-tissue disease, or clinical profiles where surgeons favour a more durable open reconstruction.

National datasets show that EVAR now accounts for most AAA repairs in several major healthcare systems. A U.S. inpatient analysis recorded 34,215 intact AAA repairs in 2019. Approximately 22,582 were standard EVAR procedures, 7,869 were complex EVAR procedures, and 3,764 were open repairs, placing the combined endovascular share near 89%.

The UK recorded 2,511 elective intact infrarenal repairs in 2024, with EVAR representing 62% and open surgery 38%. Australia and New Zealand reported 2,145 registry-recorded AAA repairs in 2024, including 1,668 EVAR and 477 open procedures, giving EVAR a 77.8% share. South Korea recorded 1,161 EVAR procedures in 2022, up from 406 in 2010. Across these datasets, EVAR represented approximately 62%–89% of repair activity, depending on the country, case mix, and inclusion of complex endovascular procedures.

 

EVAR Leads Global Revenue

EVAR accounted for an estimated 76% of global treatment revenue in 2025, supported by its dominant procedure share, higher implant value, shorter hospitalization, and expanding use in difficult anatomy. Open repair retained an estimated 24% share through patients unsuitable for endovascular treatment, infected aneurysms, younger selected patients, and hospitals without advanced complex-EVAR capability. Stent grafts, delivery systems, guidewires, imaging, and procedure-planning services concentrate more revenue per case in the endovascular pathway.

 

Elective Procedures Generate Most Revenue

Elective and intact aneurysm repair represented an estimated 84% of market revenue in 2025. Scheduled procedures support detailed CT planning, anatomical sizing, advance graft procurement, and lower perioperative risk. Ruptured and urgent repairs accounted for approximately 16%. Their procedure volume is smaller, but emergency inventory, intensive care, blood management, longer hospital stays, and greater clinical complexity increase hospital expenditure per case.

 

Specialized Vascular Hospitals Dominate Purchasing

Hospitals and specialized vascular centres generated an estimated 92% of treatment revenue in 2025. EVAR and open repair require operating theatres, fluoroscopic imaging, anaesthesia, intensive-care support, and trained vascular teams. Ambulatory facilities participate mainly in diagnostic imaging and follow-up. Device selection is concentrated among vascular surgeons, multidisciplinary aortic teams, procurement committees, and hospital value-analysis groups.

 

North America Maintains the Largest Revenue Base

North America accounted for an estimated 42% of global revenue in 2025. High procedure intensity, established EVAR reimbursement, broad access to complex devices, advanced vascular centres, and comparatively high implant prices support regional leadership. Europe maintains mature screening and registry infrastructure, while Asia-Pacific is gaining importance through population ageing, expanding CT use, improving vascular capacity, and rising EVAR adoption in South Korea, Japan, China, and Australia.

 

Shorter Recovery Gives EVAR an Operational Advantage

UK registry data for 2024 reported a median hospital stay of two days after elective EVAR compared with seven days after open repair. Observed in-hospital mortality was 0.3% after EVAR and 3.1% after open repair, while return to theatre occurred in 2.6% and 8.6% of patients, respectively.

Open-repair patients may have more difficult anatomy or different clinical risks, so these outcomes should not be treated as a randomized comparison. Hospitals nevertheless gain a clear operating advantage when suitable patients can leave sooner, require fewer postoperative resources, and release beds for other vascular cases.

 

Screening Feeds Surveillance and Elective Repair

Ultrasound screening identifies aneurysms before rupture and directs patients either into surveillance or surgical assessment. During the 2024–2025 screening year, 337,752 men were offered organized AAA screening, and 82.3% were tested. The programme detected 1,907 aneurysms, maintained 14,696 men under surveillance, and completed 22,931 surveillance scans. Only 728 patients with large or rapidly growing aneurysms who were suitable for intervention and had not declined treatment were referred appropriately for surgery.

Other national programmes add recurring ultrasound demand. Scotland completed 35,144 initial and surveillance scans in the year ending March 2025. Wales recorded at least 18,340 first-screen participants in 2023–2024. Sweden invites approximately 50,000 men annually and completes an estimated 39,500–41,500 screening ultrasounds based on participation rates of 79%–83%.

Screening, surveillance, and repair represent separate procedure categories. Initial screening is usually performed once, surveillance may continue for years, and only a small proportion of monitored patients reach the surgical threshold in any single year.

 

Incidental CT Detection Broadens the Diagnostic Funnel

Ultrasound remains the main population-screening method, while CT angiography is central to treatment planning and frequently detects aneurysms during examinations for unrelated conditions. A seven-hospital Japanese study of 1,666 asymptomatic AAA patients found that 1,352, or 81.2%, were diagnosed through CT. Ultrasound accounted for 252 diagnoses, or 15.2%, and MRI accounted for 38, or 2.3%.

Approximately 80.4% of aneurysms in the cohort were discovered during examinations for another disease. Radiology departments and automated CT-analysis tools may therefore identify patients who would otherwise remain outside formal screening programmes.

 

Treatment Delays Leave Eligible Patients Waiting for Repair

The median time from vascular assessment to elective AAA repair reached 81 days in the UK in 2024, and only 33% of patients received treatment within eight weeks. At two vascular units, one-quarter of patients waited longer than 220 days. Operating-room availability, imaging, anaesthesia, critical-care beds, vascular staffing, and referral coordination all influence how quickly eligible patients reach surgery.

The registry also recorded 1,418 urgent unruptured aortic aneurysm procedures during 2022–2024. These patients had a median aneurysm diameter of 6.5 cm and poorer outcomes than planned elective patients. Faster referral, better scheduling, and additional vascular-centre capacity could move more cases into lower-risk planned treatment.

 

Complex EVAR Increases Device Value per Procedure

Fenestrated EVAR and branched EVAR treat aneurysms located close to or involving renal and visceral arteries. These procedures require advanced CT planning, specialist teams, customized or highly configurable devices, and more technical support than standard infrarenal EVAR.

Between 2022 and 2024, UK vascular units reported 1,532 complex endovascular procedures, including 1,216 FEVAR and 290 BEVAR cases, compared with 253 complex open repairs. Complex endovascular procedures outnumbered complex open surgery by more than six to one. Reported postoperative mortality was 1.5% following complex endovascular repair and 9.9% after complex open repair, although patient selection differences remain significant.

Manufacturers are also expanding approved anatomical ranges. The FDA broadened the indication for Gore’s Excluder Conformable AAA Endoprosthesis in 2024 to include proximal neck angulation of up to 90 degrees and a minimum neck length of 10 mm. Broader indications allow vascular teams to treat some patients who previously required open surgery, off-label EVAR, or continued observation.

 

Ruptured AAA Requires Dedicated Emergency Capability

Ruptured aneurysms form a smaller but resource-intensive treatment segment. The UK recorded 315 ruptured AAA repairs in 2024, with EVAR used in 46% of cases, up from 30% in 2018. Across 2022–2024, overall in-hospital postoperative mortality after rupture repair was 34.8%.

Hospitals need continuous access to CT, suitable stent-graft inventory, hybrid theatres, vascular anaesthesia, radiographers, and trained surgical teams to offer emergency EVAR. In July 2026, the FDA approved updated Gore labelling incorporating clinical evidence for appropriately selected ruptured-AAA patients and removed the previous warning that the Excluder systems had not been evaluated in rupture. Broader on-label support may improve physician confidence, but anatomy and emergency infrastructure will continue to determine adoption.

 

Post-EVAR Surveillance Sustains Long-Term Procedure Demand

EVAR reduces the intensity of the initial hospital episode but requires continued imaging to detect endoleaks, graft migration, loss of seal, limb occlusion, aneurysm expansion, and other complications.

The UK registry reported Type 1 endoleaks in 5% and Type 2 endoleaks in 14% of elective EVAR cases. Vascular units recorded 726 elective and 373 non-elective revision procedures between 2022 and 2024. These included 359 graft relinings, 337 distal extensions, 193 endoleak embolization procedures, and 132 graft explants. Revision procedures create additional demand for imaging, secondary devices, specialist intervention, and hospital follow-up, while also increasing payer scrutiny of graft durability and total treatment cost.

FDA action involving the Endologix AFX system over Type III endoleak concerns illustrates the commercial consequences of late device failure. Recalls, intensified surveillance, and loss of surgeon confidence can shift hospital purchasing toward competing platforms with stronger long-term evidence.

 

Drug Research Targets the Gap Between Surveillance and Surgery

No FDA-approved medicine has been proven to stop or reverse AAA growth. Beta-blockers, angiotensin receptor blockers, statins, and other cardiovascular medicines may be used to manage hypertension, cholesterol, and associated vascular risk, but they do not provide definitive aneurysm repair. Metformin, anti-inflammatory agents, nucleic-acid therapies, nanocarriers, and regenerative approaches remain investigational.

Nectero Therapeutics is developing the EAST System for small and medium-sized aneurysms. The system delivers pentagalloyl glucose directly into the aneurysm wall through a dual-balloon catheter and is being evaluated against active surveillance in the randomized 400-patient Phase II/III stAAAble study for aneurysms measuring 3.5–5.0 cm. FDA Fast Track and Breakthrough Therapy designations have accelerated regulatory interaction.

Two Category III CPT codes were approved in 2025 for percutaneous and open delivery of the investigational treatment. Nectero reported two-year first-in-human data in April 2026, although the system remains investigational and unavailable for commercial sale. Successful development would establish a treatment option between surveillance and major repair rather than replace EVAR in large, symptomatic, or ruptured aneurysms.

 

Market Outlook

Primary AAA repair volumes may not increase uniformly across mature markets. The UK registry reported lower elective infrarenal and ruptured repair volumes over the latest three-year period, potentially reflecting reduced smoking, earlier detection, changing disease incidence, and competing mortality among older patients.

Revenue growth is more likely to come from complex endovascular repair, difficult anatomy, emergency EVAR, fenestrated and branched systems, imaging-supported procedure planning, and revision-compatible devices. Suppliers with broad anatomical indications, strong long-term evidence, reliable emergency inventory, physician training, and post-implant support will hold an advantage over manufacturers competing mainly in routine infrarenal grafts.

 

Abdominal Aortic Aneurysm Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.65 Billion
Revenue Forecast in 2032	USD 3.94 Billion
Overall Growth Rate	CAGR of 5.81% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Product Type, By Procedure Type, By End User, By Geography
By Treatment Type	Standard Endovascular Aneurysm Repair, Complex Endovascular Aneurysm Repair/Fenestrated & Branched EVAR, Open Surgical Repair
By Product Type	Aortic Stent Grafts, Fenestrated & Branched Stent Grafts, Catheters & Guidewires, Balloons & Closure Devices, Surgical Vascular Grafts, Endoleak Embolization & Revision Devices
By Procedure Type	Elective Intact AAA Repair, Ruptured/Urgent AAA Repair, Post-EVAR Revision & Secondary Intervention, Surveillance & Diagnostic Follow-Up
By End User	Hospitals & Specialized Vascular Centers, Outpatient Vascular Clinics, Diagnostic Imaging & Surveillance Centers, Emergency & Trauma-Enabled Vascular Units
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Expansion of EVAR across elective and emergency procedures Rising adoption of fenestrated and branched stent-graft systems for complex anatomy Growing AAA detection through screening and incidental CT imaging
Customization Option	Available upon request